Business news

    Clarity Pharmaceuticals (ASX:CU6) recruits world leading expert in copper-67 production

    Article Image

    Clarity Pharmaceuticals (ASX:CU6) has announced the appointment of Jon Stoner, the world leading expert in copper-67 isotope (Cu-67 or 67Cu) production, to its Scientific Advisory Board.

    The clinical-stage radiopharmaceutical company says Mr Stoner is the director of the Idaho Accelerator Center (IAC) and has over 10 years of experience in production of the copper-67 isotope.

    It also says Mr Stoner has 3 patents and 11 related publications.

    Clarity Pharmaceuticals is focused on developing next-generation products to improve treatment outcomes for children and adults with cancer and Stoner's expertise will help them progress their clinical trials and move towards high-volume manufacture of copper-67.

     

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa